Abstract
Aims To describe patterns of weight change amongst adults living in England with Type 2 Diabetes (T2D) and/or hypertension during the COVID-19 pandemic.
Design and Setting With the approval of NHS England, we conducted an observational cohort study using the routinely collected health data of approximately 40% of adults living in England, accessed through the OpenSAFELY service inside TPP.
Method We estimated individual rates of weight gain during the pandemic (δ). We then estimated associations between clinical and sociodemographic characteristics and rapid weight gain (>0.5kg/m2/year) using multivariable logistic regression.
Results We extracted data on adults with T2D (n=1,231,455, 44% female, 76% white British) or hypertension (n=3,558,405, 50% female, 84% white British). Adults with T2D lost weight overall (median δ = -0.1kg/m2/year [IQR: -0.7, 0.4]), however, rapid weight gain was common (20.7%) and associated with sex (male vs female: aOR 0.78[95%CI 0.77, 0.79]); age, older age reduced odds (e.g. 60-69-year-olds vs 18-29-year-olds: aOR 0.66[0.61, 0.71]); deprivation, (least-deprived-IMD vs most-deprived-IMD: aOR 0.87[0.85, 0.89]); white ethnicity (Black vs White: aOR 0.70[0.69, 0.71]); mental health conditions (e.g. depression: aOR 1.13 [1.12, 1.15]); and diabetes treatment (non-insulin treatment vs no pharmacological treatment: aOR 0.68[0.67, 0.69]). Adults with hypertension maintained stable weight overall (median δ = 0.0kg/m2/year [-0.6, 0.5]), however, rapid weight gain was common (24.7%) and associated with similar characteristics as in T2D.
Conclusion Amongst adults living in England with T2D and/or hypertension, rapid pandemic weight gain was more common amongst females, younger adults, those living in more deprived areas, and those with mental health conditions.
How this fits in Previous studies, in the general population, have reported female sex, deprivation and comorbid mental health conditions increased risk of unhealthy weight gain during the pandemic, but it is not clear whether people living with hypertensions and/or type 2 diabetes experienced the same trends.
We found that, during the pandemic, adults with hypertension maintained a stable weight whilst those with type 2 diabetes lost weight overall. However, underlying these overall trends, rapid weight gain was common amongst people with type 2 diabetes (20.7%) or hypertension (24.7%)), with female sex, younger age, deprivation, and comorbid mental health conditions associated with an increased odds of rapid weight gain in both populations.
We have identified clinical and sociodemographic characteristics of individuals with hypertension and/or type 2 diabetes who could benefit from primary care interventions on weight and health behaviours to combat health inequalities in patterns of weight gain that were exacerbated by the pandemic.
Competing Interest Statement
MS salary costs have been supported through a National Institute for Health and Care Research funded academic clinical fellowship in primary care (NIHR ACF-2017-19-006) and NIHR grant funding (NIHR AI-MULTIPLY Consortium NIHR203982). RYP is supported by the EPSRC Centre for Doctoral Training in Health Data Science (EP/S02428X/1). RYP was previously employed as a data scientist for the Bennet Institute which is funded by grants from the Bennett Foundation, Wellcome Trust, NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, Mohn-Westlake Foundation. SVE is funded by a Diabetes UK Sir George Alberti research training fellowship (grant number: 17/0005588). FE salary cost is supported by MRC (MR/S027297/1). DS is funded by the NIHR (NIHR203982). AM is a senior clinical researcher at the University of Oxford in the Bennett Institute, which is funded by grants from the Bennett Foundation, Wellcome Trust, NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, Mohn-Westlake Foundation. AM has consulted for https://inductionhealthcare.com/. AM is a member of the RCGP health informatics group and the NHS Digital GP data Professional Advisory Group that advises on access to GP Data for Pandemic Planning and Research (GDPPR); payment direct to me for the GDPPR role. BG has received research funding to the Bennett Institute from the Bennett Foundation (ongoing), the Laura and John Arnold Foundation (past), the NIHR (ongoing), the NIHR School of Primary Care Research (past), the NIHR Oxford Biomedical Research Centre (past), the Mohn-Westlake Foundation (ongoing), NIHR Applied Research Collaboration Oxford and Thames Valley (ongoing), the Wellcome Trust (ongoing), the Good Thinking Foundation (ongoing), Health Data Research UK (past), the Health Foundation (past), the World Health Organization (past), UKRI (ongoing), Asthma UK (past), the British Lung Foundation (past), and the Longitudinal Health and Wellbeing strand of the National Core Studies programme (ongoing); he also receives a personal income from speaking and writing for lay audiences on the misuse of science. RM is supported by Barts Charity (MGU0504). JV is National Clinical Director for Diabetes & Obesity at NHS England. BMK is also employed by NHS England. KK is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and the NIHR Leicester Biomedical Research Centre (BRC). KK has acted as a consultant, speaker or received grants for investigator-initiated studies for Astra Zeneca, Bayer, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme, Boehringer Ingelheim, Oramed Pharmaceuticals, Roche and Applied Therapeutics. SF has received grants from the NIHR (NIHR 31672, NIHR 202635) and MRC (MR/W014416/1, MR/V004905/1, MR/S027297/1). SF, RM, CM are part of the Genes & Health programme, which is part-funded (including salary contributions) by a Life Sciences Consortium comprising Astra Zeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc. This research used data assets made available as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). In addition, the OpenSAFELY Platform is supported by grants from the Wellcome Trust (222097/Z/20/Z); MRC (MR/V015757/1, MC_PC-20059, MR/W016729/1); NIHR (NIHR135559, COV-LT2-0073), and Health Data Research UK (HDRUK2021.000, 2021.0157).
Funding Statement
The study did not receive any specific funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the London School of Hygiene & Tropical Medicine Ethics Board (reference 26536).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Detailed pseudonymised patient data is potentially re-identifiable and therefore not shared. All code for data management and analysis, as well as codelists, are shared openly for review and re-use under MIT open license, available at https://github.com/opensafely/BMI-and-Metabolic-Markers.
